Loading provider…
Loading provider…
Hematology (Internal Medicine) Physician in Charlotte, NC
NPI: 1114160082Primary Practice Location
CAROLINAS MEDICAL CENTER/BEHAV HEALTH
501 Billingsley Rd, Charlotte, NC
Primary Employer
Levine Cancer Institute
atriumhealth.org
HQ Phone
Get MD Ryan's Phone Numberphone_androidMobile
Get MD Ryan's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardNC State Medical License
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99214Established patient office or other outpatient visit, 30-39 minutes | 101 | 144 |
| 2 | 99215Established patient office or other outpatient, visit typically 40 minutes | 84 | 323 |
| 3 | 99205New patient office or other outpatient visit, typically 60 minutes | 13 | 13 |
Consensus Recommendations from the 2024 Lymphoma Research Foundation Workshop on Treatment Selection and Sequencing in CLL or SLL.
Authors: Marc Hoffmann, Adam Kittai, Andrew Lipsky, Daniel Ermann, Inhye Ahn, Jacob Soumerai, Jacqueline Barrientos, Meghan Thompson, Catherine Coombs
Publication Date: 2024-08-12
The shrinking role of chemotherapy in the treatment of chronic lymphocytic leukemia.
Authors: Saad Usmani, Nilanjan Ghosh, Farrukh Awan, Lori Leslie
Journal: Expert Rev Hematol
Publication Date: 2016-11-14
Authors: Edward Copelan, Bei Hu, Nilanjan Ghosh, Ruben Mesa, Belinda Avalos
Journal: Transplant Cell Ther
Publication Date: 2024-09-11
Lead Sponsor: Loxo Oncology, Inc.
Collaborators: Eli Lilly and Company
Intervention / Treatment: DRUG: Acalabrutinib, DRUG: Ibrutinib, DRUG: Zanubrutinib, DRUG: Pirtobrutinib
Lead Sponsor: National Cancer Institute (NCI)
Intervention / Treatment: PROCEDURE: Magnetic Resonance Imaging, OTHER: Questionnaire Administration, BIOLOGICAL: Nivolumab, PROCEDURE: Positron Emission Tomography, PROCEDURE: Biospecimen Collection, BIOLOGICAL: Pegfilgrastim, OTHER: Quality-of-Life Assessment, RADIATION: Radiation Therapy, DRUG: Dacarbazine, DRUG: Brentuximab Vedotin, PROCEDURE: Computed Tomography, BIOLOGICAL: Filgrastim, DRUG: Vinblastine Sulfate, DRUG: Doxorubicin Hydrochloride
Lead Sponsor: Loxo Oncology, Inc.
Collaborators: Eli Lilly and Company
Intervention / Treatment: DRUG: Venetoclax, DRUG: Rituximab, DRUG: Pirtobrutinib